GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Orion Infusions Ltd (DHA:ORIONINFU) » Definitions » EBIT

Orion Infusions (DHA:ORIONINFU) EBIT : BDT87.5 Mil (TTM As of Dec. 2024)


View and export this data going back to . Start your Free Trial

What is Orion Infusions EBIT?

Orion Infusions's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2024 was BDT23.0 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2024 was BDT87.5 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Orion Infusions's annualized ROC % for the quarter that ended in Dec. 2024 was 9.09%. Orion Infusions's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 14.92%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Orion Infusions's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 1.07%.


Orion Infusions EBIT Historical Data

The historical data trend for Orion Infusions's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orion Infusions EBIT Chart

Orion Infusions Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 77.94 81.12 94.77 79.81 85.17

Orion Infusions Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.72 18.43 22.07 23.96 23.04

Competitive Comparison of Orion Infusions's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Orion Infusions's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orion Infusions's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orion Infusions's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Orion Infusions's EV-to-EBIT falls into.


;
;

Orion Infusions EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT87.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Orion Infusions  (DHA:ORIONINFU) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Orion Infusions's annualized ROC % for the quarter that ended in Dec. 2024 is calculated as:

ROC % (Q: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2024 ) + Invested Capital (Q: Dec. 2024 ))/ count )
=90.652 * ( 1 - 21.37% )/( (780.669 + 787.634)/ 2 )
=71.2796676/784.1515
=9.09 %

where

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=825.307 - 78.019 - ( 20.692 - max(0, 473.928 - 440.547+20.692))
=780.669

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=844.116 - 103.079 - ( 12.849 - max(0, 505.396 - 458.799+12.849))
=787.634

Note: The Operating Income data used here is four times the quarterly (Dec. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Orion Infusions's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2024  Q: Dec. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=92.164/( ( (362.085 + max(256.073, 0)) + (361.734 + max(255.624, 0)) )/ 2 )
=92.164/( ( 618.158 + 617.358 )/ 2 )
=92.164/617.758
=14.92 %

where Working Capital is:

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(162.345 + 100.087 + 157.423) - (78.019 + 0 + 85.763)
=256.073

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(138.953 + 147.523 + 159.474) - (103.079 + 0 + 87.247)
=255.624

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Orion Infusions's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2024 )
=87.498/8202.582
=1.07 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Orion Infusions EBIT Related Terms

Thank you for viewing the detailed overview of Orion Infusions's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Orion Infusions Business Description

Traded in Other Exchanges
N/A
Address
153-154 Tejgaon I/A, Orion House, Dhaka, BGD, 1208
Orion Infusions Ltd is a pharmaceutical company. It produces various types of intravenous fluids, rehydration solutions, electrolyte solutions, antimicrobial products, and other pharmaceutical products in Bangladesh. The products of the company include Dextrolac, Dextropac, Dextrosal, Dianak, Electro dex, fructose, Hartman, Intralipid, Manisol, Maprocin, Nidazyl, Orlev, Ortac, Plasmasol, Proliv, and Salpac. In addition, the company is also involved in activities related to cosmetics and toiletries, infrastructure development, real estate and construction, power, agro products, hospitality, textiles and garments, and aviation management sectors. Geographically, it operates in Bangladesh.

Orion Infusions Headlines

No Headlines